Skip to search formSkip to main contentSkip to account menu

TLK 286

Known as: TLK-286, TLK286 
A modified glutathione analog. TLK286 is selectively activated by glutathione S-Transferase P1-1 into an alkylating metabolite which forms covalent… 
National Institutes of Health

Related topics

Related topics

3 relations
TER 286

Narrower (2)

Telcytacanfosfamide HCl

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2009
Review
2009
Randomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer (OC).
5552 Background: Canfosfamide (C) is a glutathione analog prodrug activated by glutathione S-transferase P1-1. C is synergistic… 
Review
2007
Review
2007
Phase 3 Study: Canfosfamide (C, TLK286) plus carboplatin (P) vs liposomal doxorubicin (D) as 2nd line therapy of platinum (P) resistant ovarian cancer (OC)
LBA5529 Background: Canfosfamide (C) is a novel glutathione analog prodrug activated by glutathione S-transferase P1–1. C has… 
2007
2007
Liposuktionskürettage versus Botox® bei axillärer Hyperhidrosis
ZusammenfassungHintergrundAxilläre Hyperhidrosis ist eine Sekretionsstörung der Schweißdrüsen. Konservative Behandlungsformen… 
Review
2006
Review
2006
New developments in chemotherapy for advanced non-small cell lung cancer
Purpose of review The treatment of patients with advanced non-small cell lung cancer has changed considerably in the past decade… 
2006
2006
Multi-institutional Phase 2 Study of TLK286 (TELCYTA, a Glutathione S-transferase P1-1 Activated Glutathione Analog Prodrug) in Patients With Platinum and Paclitaxel Refractory or Resistant Ovarian…
2004
2004
Synergistic effect of TELCYTA™ (TLK286) in combination with paclitaxel, doxorubicin, carboplatin, oxaliplatin, cisplatin, docetaxel, gemcitabine and iressa in human cancer cells.
2008 TLK286 is a novel glutathione analog cancer prodrug that has shown significant antitumor activity in multiple Phase 2… 
2004
2004
Phase 1-2a study of TLK286 (a novel glutathione analog) in combination with carboplatin in platinum refractory or resistant (≥ 3rd line) ovarian cancer.
5060 Background: TLK286 (Telcyta) is a novel glutathione analog prodrug activated by GST P1-1, which is overexpressed in ovarian… 
2004
2004
Phase 1–2a study of TLK286 (a novel glutathione analog) in combination with carboplatin in platinum refractory or resistant (≥ 3rd line) ovarian cancer
5060 Background: TLK286 (Telcyta) is a novel glutathione analog prodrug activated by GST P1–1, which is overexpressed in ovarian… 
2004
2004
Phase 1-2a dose ranging study of TLK286 (a novel glutathione analog) in combination with liposomal doxorubicin in platinum refractory or resistant ovarian cancer.
5062 Background: TLK286 (Telcyta) is a glutathione analog prodrug activated by GST P1-1, which is overexpressed in ovarian cancer… 
2004
2004
Phase 1–2a dose ranging study of TLK286 (a novel glutathione analog) in combination with docetaxel in platinum-resistant non-small cell lung cancer (NSCLC)
7140 Background: TLK286 (Telcyta) is a novel glutathione analog prodrug activated by GST P1–1, which is overexpressed in NSCLC… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)